{
    "id": 2644,
    "fullName": "APC I1307K",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "APC I1307K lies within a region of the Apc protein responsible for downregulation mediated by ubiquitination (UniProt.org). I1307K has not been biochemically characterized, but has been associated with increased colorectal cancer risk (PMID: 9724771, PMID: 24416237).",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 5825,
                    "pubMedId": 9724771,
                    "title": "The APC variants I1307K and E1317Q are associated with colorectal tumors, but not always with a family history.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/9724771"
                },
                {
                    "id": 1171,
                    "pubMedId": 24416237,
                    "title": "Colorectal tumors from APC*I1307K carriers principally harbor somatic APC mutations outside the A8 tract.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24416237"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 324,
        "geneSymbol": "APC",
        "terms": [
            "APC",
            "BTPS2",
            "DESMD",
            "DP2",
            "DP2.5",
            "DP3",
            "GS",
            "PPP1R46"
        ]
    },
    "variant": "I1307K",
    "createDate": "11/28/2014",
    "updateDate": "01/27/2020",
    "referenceTranscriptCoordinates": {
        "id": 142406,
        "transcript": "NM_000038",
        "gDna": "chr5:g.112839514T>A",
        "cDna": "c.3920T>A",
        "protein": "p.I1307K",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) treatment resulted in reduced tumor size and improved clinical performance for 11 months in a patient with triple-receptor negative breast cancer which harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3673,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Nerlynx (neratinib) and Xeloda (capecitabine) combination treatment resulted in continued clinical performance improvement following progression on Neratinib (HKI-272) monotherapy in a patient with triple-receptor negative breast cancer that harbored ERBB2 L755S, along with APC I1307K, MDM2 amplification, and MYC amplification (PMID: 26358790).",
            "molecularProfile": {
                "id": 14286,
                "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp"
            },
            "therapy": {
                "id": 1543,
                "therapyName": "Capecitabine + Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3948,
                    "pubMedId": 26358790,
                    "title": "HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26358790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2472,
            "profileName": "APC I1307K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14286,
            "profileName": "APC I1307K ERBB2 L755S MDM2 amp MYC amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 142405,
            "transcript": "NM_001127510",
            "gDna": "chr5:g.112839514T>A",
            "cDna": "c.3920T>A",
            "protein": "p.I1307K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 142406,
            "transcript": "NM_000038",
            "gDna": "chr5:g.112839514T>A",
            "cDna": "c.3920T>A",
            "protein": "p.I1307K",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}